Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 19/20 | 0.78 |
| ▸ | CNR2 | P34972 | 13/20 | 0.78 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6704796 | 0.88 | CNR1 (1.00) | CNR1CNR2OPRL1 | |
| SCHEMBL4499547 | 0.88 | CNR1 (1.00) | CNR1CNR2OPRL1 | |
| SCHEMBL4496279 | 0.86 | CNR1 (1.00) | CNR1CNR2OPRL1 | |
| Dimethylamine SCHEMBL1040287 | 0.86 | CNR1 (0.96) | CNR1CNR2OPRL1 | |
| SCHEMBL4508134 | 0.85 | CNR1 (0.81) | CNR1CNR2 | |
| SCHEMBL6700506 | 0.84 | CNR1 (0.79) | CNR1CNR2 | |
| SCHEMBL675613 | 0.84 | CNR1 (0.79) | CNR1CNR2OPRL1 | |
| SCHEMBL675249 | 0.84 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL31060210 | 0.84 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL4506842 | 0.83 | CNR1 (0.77) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524867-B2 | Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity | SOLVAY PHARMACEUTICALS, B.V. (NL) | 2009-04-28 | — | — | US | disclosed |
| US-7524867-B2 | Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity | SOLVAY PHARMACEUTICALS, B.V. (NL) | 2009-04-28 | — | — | US | disclosed |
| US-7524867-B2 | Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity | SOLVAY PHARMACEUTICALS, B.V. (NL) | 2009-04-28 | — | — | US | disclosed |
| EP-1756066-B1 | TETRASUBSTITUTED IMIDAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS WITH A HIGH CB1/CB2 RECEPTOR SUBTYPE SELECTIVITY | SOLVAY PHARM BV (NL) | 2008-08-20 | — | — | EP | disclosed |
| US-7109216-B2 | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-09-19 | — | — | US | disclosed |
| US-20050267161-A1 | Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity | SOLVAY PHARMACEUTICALS B.V. | 2005-12-01 | — | — | US | disclosed |
| US-20050054679-A1 | 1 H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267161-A1 | Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity | CNR1, CNR2, TRPV1 | CNR1 1/4885CNR2 2/4885OPRL1 56/4885 |
| US-20050054679-A1 | 1 H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | CNR1, CNR2, HRH4 | CNR1 1/4885CNR2 2/4885OPRL1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.